Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4Gynecologic 3Breast 1

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 380Lymphoma 357Melanoma 335Leukemia 335Neoplasm Metastasis 322Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 282Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

olaparib 4liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Has results × Fanconi Anemia, Complementation Group D1 × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

AstraZeneca

Phase 2 Completed
54 enrolled 17 charts
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

AstraZeneca

Phase 2 Completed
97 enrolled 22 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

AstraZeneca

Phase 2 Completed
58 enrolled 13 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡